Nicotinic acetylcholine receptor agonists in the treatment...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/404 (2006.01) A61K 31/437 (2006.01) A61K 31/439 (2006.01) A61K 45/00 (2006.01) A61P 25/02 (2006.01) A61P 25/14 (2006.01) A61P 43/00 (2006.01) C07D 221/22 (2006.01)

Patent

CA 2460118

This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic actylcholine receptor agonist.

L'invention concerne l'utilisation d'agonistes du récepteur d'acétylcholine nicotinique afin de traiter les impatiences des membres inférieurs (RLS). Elle concerne également l'utilisation d'un agoniste du récepteur d'acétylcholine nicotinique afin de préparer un médicament servant à traiter les impatiences des membres inférieurs. Elle concerne également une composition pharmaceutique servant à traiter les impatiences des membres inférieurs et contenant un agoniste du récepteur d'acétylcholine nicotinique.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Nicotinic acetylcholine receptor agonists in the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nicotinic acetylcholine receptor agonists in the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotinic acetylcholine receptor agonists in the treatment... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1885799

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.